scholarly journals Efficacy of topical agents in the background therapy of atopic dermatitis in children

2018 ◽  
pp. 122-127 ◽  
Author(s):  
E. I. Danilova ◽  
O. Yu. Trusova ◽  
V. V. Sumenko
Keyword(s):  
Atopic Dermatitis ◽  
Skin Reaction ◽  
Skin Disease ◽  
Topical Agent ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Inflammatory Skin Disease ◽  
Background Therapy ◽  
The Mean ◽  
Inflammatory Skin

Atopic dermatitis (AtD) is a chronic inflammatory skin disease with complex etiopathogenesis, which begins in childhood. Purpose of the study: To evaluate the clinical efficacy and safety of Skin-cap cream as a topical background therapy in children with diabetes. Materials and methods: The study included 77 children aged 1 to 11 years with moderately severe AtD with a widespread lesion of the skin (33,5%), skin itching, inflammatory skin reaction and exacerbations occurring 3 to 4 times a year. During the study, two arms of children were formed: the treatment arm - 39 children with an average course of the disease (SCORAD index = 33,9 ± 2,2 points), who received the background therapy with the prescription of Skin-cap cream. Comparison arm: 38 children (SCORAD index = 34,2 ± 2,1 points), who received Afloderm cream as a background therapy. Results: Patients of the treatment arm showed a significant dynamics of relief of AtD symptoms as compared with the comparison arm. the differences in the duration of dermal manifestations were as follows: in the treatment arm, the time of reducing hyperaemia was 4,4 ± 1,2 days, in the comparison arm, hyperaemia was reduced at 5,7 ± 1,5 days (p< 0.05), the mean duration of alleviation of the skin itching was 3,0 ± 0,9 days and 5,8 ± 1,4 days (p< 0,05) at 6,8 and 7,3 days in the treatment arm and the comparison arm, respectively. Conclusions: The conducted study confirmed the high efficacy of the use of Skin-cap cream as a topical agent for background therapy of AtD, as compared to topical glucocorticosteroids.

scholarly journals Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis

2021 ◽  
Vol 20 (5) ◽  
pp. 376-382
Author(s):  
Nikolay N. Murashkin ◽  
Roman A. Ivanov ◽  
Eduard T. Ambarchian ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Maintenance Therapy ◽  
Skin Disease ◽  
Pediatric Population ◽  
Efficacy And Safety ◽  
Inflammatory Skin Disease ◽  
High Prevalence ◽  
Proactive Therapy ◽  
Term Maintenance

Atopic dermatitis (AtD) is multifactorial inflammatory skin disease with high prevalence in pediatric population. It is crucial to implement long-term maintenance therapy to prevent AtD exacerbations according to current clinical guidelines and expert reports. The article summarizes the results of the major studies on using pimecrolimus 1% cream. Its efficacy and safety in long-term proactive therapy of children with AtD are presented.

Therapeutic Approach of Probiotic in Children with Atopic Dermatitis

2020 ◽  
Vol 19 ◽  
Author(s):  
Sangeeta Huidrom
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disease ◽  
Developed Countries ◽  
Current Treatment ◽  
Inflammatory Skin Disease ◽  
Social Burden ◽  
The Family ◽  
Prevention And Treatment ◽  
Inflammatory Skin ◽  
Chronic Skin

: Pediatric atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease affecting 20% of children all over the world especially in developed countries. Recently, there is an increase in the prevalence rate of AD. This chronic inflammatory skin disease causes economic and social burden to the family. The exact cause of AD is not known, however recent studies suggest that imbalance of microflora present in the gut leads to AD. The current treatment of AD involves the application of moisturizer, topical corticosteroids, antihistamines and antibiotics. This line of treatment of AD in children has many side effects. An alternative novel therapeutic approached have to be explored to combat this chronic skin disease. In recent years there is increasing interest in the use of probiotic in the modulation of gut microbiota for the management of AD. Many research studies showed that administration of probiotic give positive results in the prevention and treatment of AD in children, however, the results are not consistent and conclusive. In this review, the dysbiosis of the gut flora contributes to the development of AD is addressed and clinical evidence of probiotics in the prevention and treatment of AD children is also summarises.

scholarly journals ATOPIC DERMATITIS: DIAGNOSTICS FEATURES

2012 ◽  
Vol 9 (2) ◽  
pp. 35-44
Author(s):  
D Sh Macharadze
Keyword(s):  
Atopic Dermatitis ◽  
Broad Spectrum ◽  
Skin Disease ◽  
Environmental Control ◽  
Clinical Symptoms ◽  
Food Allergens ◽  
Inflammatory Skin Disease ◽  
Allergen Avoidance ◽  
Inflammatory Skin

Atopic dermatitis (AD) — a chronic inflammatory skin disease with a broad spectrum of clinical symptoms. It is diagnosed mainly clinically. Sensitization to inhalled and food allergens may play a role in the development of AD. Thus, it is important to determine the presence of sensitization for environmental control and allergen avoidance, pharmacotherapy, and immunotherapy.

scholarly journals From Emollients to Biologicals: Targeting Atopic Dermatitis

2021 ◽  
Vol 22 (19) ◽  
pp. 10381
Author(s):  
Lorenzo Salvati ◽  
Lorenzo Cosmi ◽  
Francesco Annunziato
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disease ◽  
Clinical Presentation ◽  
Age Groups ◽  
Inflammatory Skin Disease ◽  
Clinical Phenotypes ◽  
Inflammatory Skin

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.

scholarly journals Atopic Dermatitis: Natural History, Diagnosis, and Treatment

ISRN Allergy ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Simon Francis Thomsen
Keyword(s):  
Atopic Dermatitis ◽  
Natural History ◽  
Clinical Features ◽  
Skin Disease ◽  
Early Onset ◽  
Diagnosis And Treatment ◽  
Lifetime Prevalence ◽  
Inflammatory Skin Disease ◽  
Inflammatory Skin

Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime prevalence of approximately 20%. The aetiology of atopic dermatitis is unknown, but the recent discovery of filaggrin mutations holds promise that the progression of atopic dermatitis to asthma in later childhood may be halted. Atopic dermatitis is not always easily manageable and every physician should be familiar with the fundamental aspects of treatment. This paper gives an overview of the natural history, clinical features, and treatment of atopic dermatitis.

scholarly journals Pathogenesis of atopic dermatitis: Current concepts

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Jayamini Seneviratne
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Picture ◽  
Skin Disease ◽  
Skin Barrier ◽  
Inflammatory Skin Disease ◽  
Primary Defect ◽  
Established Disease ◽  
Inflammatory Skin

Atopic dermatitis is the most common, yet more troublesome, inflammatory skin disease affecting mankind and its prevalence is increasing globally. In established disease, inflammation and pruritus dominate the clinical picture. Thanks to a group pioneering of dermatological scientists, we are now beginning to understand how inflammation is initiated by a primary defect in the epidermal skin barrier.

IL-13 antagonists in the treatment of atopic dermatitis

Immunotherapy ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 327-344
Author(s):  
Carla Tubau ◽  
Lluís Puig
Keyword(s):  
Monoclonal Antibody ◽  
Clinical Trials ◽  
Atopic Dermatitis ◽  
Small Molecules ◽  
Skin Disease ◽  
Skin Diseases ◽  
Inflammatory Skin Disease ◽  
Receptor Alpha ◽  
Inflammatory Skin

Atopic dermatitis (AD) is a prevalent inflammatory skin disease. IL-13 contributes significantly to the pathogenesis of AD in several ways, and beneficial results have been demonstrated with anti-IL-13 therapies. Currently, the only monoclonal antibody (mAb) approved for AD treatment is dupilumab, an antagonist of the IL-4 receptor alpha (IL-4Rα) subunit common to IL-4 and IL-13 receptors, but clinical trials evaluating anti-IL-13 mAbs are providing promising results. The topics of this review will be mAbs targeting IL-13 for the treatment of AD such as dupilumab, tralokinumab and lebrikizumab, small molecules targeting the IL-13 pathway, and a brief explanation of therapies targeting IL-13 for the treatment of other skin diseases.

Sign in / Sign up

Export Citation Format

Share Document